Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Risk Panel DXM Meeting Raises Stakes on Age Restriction Movement

This article was originally published in The Tan Sheet

Executive Summary

A Drug Safety and Risk Management Advisory Committee meeting scheduled for Sept. 14 on the potential for abuse of the cough suppressant dextromethorphan could bring the OTC industry's next regulatory nightmare
Advertisement

Related Content

Consumer OTC Ingredient Survey Reveals Need For Education
Consumer OTC Ingredient Survey Reveals Need For Education
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
FDA Panel Says Leave DXM Unscheduled For Now, Urges Congressional Action
NDAC Veterans Join DSaRM Advisory Panel For DXM Safety Meeting
FDA Panel To Weigh DXM Education, Sales Restrictions Against Scheduling
Wolfe Absence May Have Disarming Effect On DXM Safety Panel
Senate Meth Fight Pits Rx-Only Pseudoephedrine Against E-Tracking Option
Annual survey shows OTC product abuse flat in 2009
“Snurf” Abuse Reports Revive Interest In DXM Bills

Topics

Advertisement
UsernamePublicRestriction

Register

PS104087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel